248 words Introduction: 535 words Discussion: 998 words Abbreviations used are: CYP, Cytochrome P450; Da, Daltons; DQFCOSY, double-quantum filtered correlation spectroscopy; HPLC, high performance liquid chromatography; HMBC, heteronuclear multiple bond correlation; HRP, horse-radish peroxidase; HSQC, heteronuclear single-quantum coherence; LC/MS, liquid chromatography/mass spectrometry; MS/MS, tandem mass spectrometry; NMR, nuclear magnetic resonance spectroscopy; TOCSY, total correlation spectroscopy; VCR, vincristine; VRL, vinorelbine; 1D ZQFTOCSY, one dimensional zeroquantum filtered total correlation spectroscopy. vincristine was incubated with a library of cDNA-expressed CYPs, and the major oxidative metabolites were identified. CYP3A4 and CYP3A5 were the only CYPs to support substantial loss of parent drug and formation of the previously unidentified, major metabolite (M1). The structure of M1, arising as a result of an oxidative cleavage of the piperidine ring of the dihydrohydroxycantharanthine unit of vincristine, was conclusively established after conversion to suitable derivatives followed by spectroscopic analysis, and a new pathway for vincristine metabolism is proposed. CYP3A5 was more efficient in catalyzing the formation of M1 compared to CYP3A4 (9 to 14-fold higher intrinsic clearance for CYP3A5). The formation of M1 was stimulated (3-fold) by the presence of co-expressed cytochrome b 5 , but the relative efficiencies of M1 formation by CYP3A4 and CYP3A5 were unaffected. Our findings demonstrate that in contrast to most CYP3A biotransformations, the oxidation of vincristine is considerably more efficient with CYP3A5 than CYP3A4. We conclude that common genetic polymorphisms in CYP3A5 expression may contribute to the interindividual variability in the systemic elimination of vincristine.
Introduction
The treatment of pediatric acute lymphoblastic leukemia (ALL) includes vincristine as one of the core drugs in induction. For these patients, high interindividual variability in efficacy and toxicity with significant differences in outcomes between ethnic groups have been reported. In one acute lymphoblastic leukemia (ALL) study, controlling for compliance, African-American children had a 42% increased mortality rate compared to Caucasian children (Pollock et al., 2000) . Event-free-survival (EFS) was only 54% for African-American children compared to a Caucasian EFS of 82% in another ALL study (Lange et al., 2002) . Unpredictable but treatmentlimiting neurotoxicity has resulted in the arbitrary use of a maximum dose of 2 mg despite known differences in drug exposure between patients (McCune and Lindley, 1997) . Early vincristine clinical studies showed up to 11-fold variability in drug exposure (dose-corrected AUC) between adult patients (Van den Berg et al., 1982) . More recent pediatric clinical pharmacokinetic studies also reported a 19-fold difference in the dose-corrected AUC (Frost et al., 2003) . Understanding determinants of the variation in vincristine exposure may allow identification of patient-specific risk factors for neurotoxicity or individualized dosing strategies to decrease the risk of patient relapse.
Evidence from in vitro and in vivo studies supports a determinant role for CYP3A-mediated metabolism in the systemic elimination of vincristine. The metabolism of structurally-related compounds, vinblasine and vindesine, with human liver microsomes was inhibited by vincristine and other CYP3A-selective inhibitors which suggest that CYP3A participates in the metabolism of vincristine Zhou-Pan et al., 1993) . In addition, numerous clinical drug-drug interactions with itraconazole and nifedipine have been reported for vincristine, and
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Page 5 of 38 the observed increases in neurotoxicity are consistent with the CYP3A-mediated metabolism of vincristine (Sathiapalan and El-Solh, 2001; Bohme et al., 1995; Kamaluddin et al., 2001; Fedeli et al., 1989) . The genetically polymorphic expression of the CYP3A5 enzyme may contribute to the clinically observed interindividual and inter-racial variability in vincristine response. Over 70% of African-Americans have at least one CYP3A5*1 allele which allows expression of active CYP3A5, but the CYP3A5*1 allele is only present in 10-20% of Caucasians (Xie et al., 2004) .
CYP3A4 is normally considered the major metabolizing enzyme in the CYP3A family (Williams et al., 2002) . However, for individuals with the CYP3A5*1 allele, CYP3A5 can represent more than 50% of the total CYP3A content in human liver microsomes (Huang et al., 2004) . CYP3A5 genotype dependent drug clearance is well established for tacrolimus, a substrate oxidized by CYP3A4 and CYP3A5 with relatively equal efficiencies in vitro (MacPhee et al., 2002; Kamdem et al., 2005) .
Despite the evidence implicating CYP3A enzymes in the primary metabolic elimination of vincristine, the relative contributions of the drug-metabolizing CYPs to the oxidation of vincristine along with the structural identities of the primary oxidative metabolites remain to be determined (Zhou et al., 1994) . These deficiencies preclude an understanding of the genetic and environmental factors that may contribute to the interindividual variability in vincristine disposition. In addition, the roles of primary and subsequent metabolites to the efficacy and toxicity of this important chemotherapeutic agent are unknown. Therefore, the objectives of this study were to identify the major metabolites from the CYP-mediated metabolism of vincristine and to determine the relative contributions of the major drug-metabolizing CYPs to vincristine metabolism in vitro.
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Methods

Chemicals and cDNA-expressed human CYPs
Vincristine sulfate (98%, see Fig. 1 were of HPLC grade and were purchased from Fisher Scientific (Pittsburgh, PA).
Purification of vincristine
For key experiments, vincristine was purified by HPLC prior to use because vincristine-related impurities were present in the commercially available vincristine, including a compound that coeluted with the major metabolite M1 (see below). A vincristine standard curve with vinorelbine as an internal standard was used to quantify the concentration of vincristine in the HPLC fractions. Prior to use, the fractions containing purified vincristine were evaporated to dryness at room temperature. 3 H-vincristine sulfate was also purified using this procedure.
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or CYP3A5 were used with and without cytochrome b 5 to minimize variability. The incubation conditions for CYP3A4 (25 or 50 pmol, 15 min, 500 µl incubation) and CYP3A5 (25 pmol, 3 min, 500 µl incubation) reactions were determined based on the HPLC assay limits of quantitation and linear conditions. To determine linearity, different CYP concentrations and incubation times were tested, and the best conditions were selected in which less than 15% of the parent was metabolized. Microsomes without CYPs (insect cell control Supersomes) were utilized as negative controls.
For the radiolabelled vincristine incubations, vincristine at approximately 10 µM (2x10 6 dpm per incubation) was used. CYP3A4 with co-expressed b 5 (12.5 pmol), CYP3A5 with co-expressed b 5 (25 pmol), and control insect microsomes (matched by CYP3A5 protein content) were incubated with the radiolabelled vincristine for 15 min at a final volume of 250 µl.
LC/UV/radioactivity analysis
The HPLC system used was an Agilent 1100 Series (Wilmington, DE) and a Hewlett Packard 1050 Series UV detector (Wilmington, DE) . Chromatographic separation of M1, M2, vincristine, and vinorelbine (internal standard) was achieved with a C 18 column (Inertsil ODS3, 3.0 x 150 mm, 5-µm particle size; MetaChem Technologies Inc., Torrance, CA) at a flow rate of 0.4 ml/min. The mobile phase consisted of 0.2% formic acid (mobile phase A) and methanol (mobile phase B). Analytes were eluted using a series of linear gradients: 0 min/20% B, 7 min/20% B, 42 min/56% B, 42.1 min/80% B, 52 min/80% B, 52.1 min/20% B. The parent drug and metabolites were detected by ultraviolet absorbance at a wavelength of 254 nm. To allow quantification of M1 by HPLC using a vincristine standard curve, the extinction coefficients of
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The metabolites were also quantified after incubation of radiolabelled vincristine with the CYPs followed by HPLC. Fractions were collected in 20-second aliquots, and the radioactivity of each fraction was determined by liquid scintillation counting (LS3801 scintillation counter; Beckman, Fullerton, CA) with 5 ml of scintillation cocktail (ScintiVerse; Fisher Scientific Co., Fair Lawn, NJ).
Preparation of vincristine metabolites and derivatives
M1 and M1-acetate: Vincristine (not purified) at 30 µM was pre-incubated with recombinant CYP3A5 (100 pmol) and 100 mM Na 2 HPO 4 with 5 mM MgCl 2 , pH 7.4 (total volume 1 ml). The reaction was started with the addition of NADPH (0.5 mM final concentration). After 40 min, the incubation was extracted with methylene chloride (1 ml). M1 was then isolated by HPLC (see above), and the appropriate M1 eluent fractions were pooled. The product was extracted with methylene chloride (6 ml), and the solvent was evaporated at room temperature to yield M1.
M1-acetate was prepared by mixing M1 and 100 µl of neat acetic anhydride at room temperature. After 30 min, the reaction was quenched with 200 µl of water and extracted with methylene chloride (3x1ml). The organic extract was dried and reconstituted in the HPLC mobile phase prior to LC/MS/MS analysis.
M2 with peroxidase:
Larger quantities of M2 were prepared by the oxidation of vincristine by horseradish peroxidase (HRP) and hydrogen peroxide, a procedure previously described (Ahn et al., 1997) with slight modifications. Briefly, vincristine sulfate (1.5 mg) was dissolved in 7 ml of
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Page 10 of 38 100 mM Na 2 HPO 4 at 37°C. A solution of HRP (1.2 mg), 100 mM Na 2 HPO 4 buffer (350 µl), and hydrogen peroxide (125 µl, final reaction concentration 0.4 mM) was added to the vincristine solution and incubated at 37°C in a shaking water bath for 2h. The final mixture was extracted with methylene chloride (6 ml), and the organic extract was dried at room temperature. The residue was purified by HPLC, and the eluent fractions were dried to yield M2 (0.5 mg).
M3: Vincristine (not purified) at 30 µM was pre-incubated with recombinant CYP3A5 (100 pmol) and 100 mM Na 2 HPO 4 with 5 mM MgCl 2 , pH 7.4 (total volume 1 ml). The reaction was initiated with the addition of NADPH (0.5 mM final concentration). After 40 min, the incubation was quenched with ethyl acetate (0.5 ml) and 5N NaOH (100 µl). Additional ethyl acetate (3 ml) was added, and the organic layer was evaporated. The resulting residue was purified by HPLC as described above to yield M3. M3 was also prepared directly from the purified M1 by mixing M1 with water (1 ml) and 5N NaOH (20 µl) followed by extraction with ethyl acetate (1 ml). ZQFTOCSY experiment (Bradley et al., 2005) was performed to identify proton chemical shifts in the extremely crowded regions.
LC/MS analysis
Data Analysis
For incubations with cDNA-expressed CYP3A4 or CYP3A5, the Michaelis-Menten constants (K m ) and maximal rates of metabolism (V max ) were determined by fitting the data to a one- 
Results
CYP screen
Screening experiments with a panel of recombinant enzymes revealed that CYP3A4 and CYP3A5 are the major CYPs that metabolize vincristine as shown by parent drug disappearance and M1 formation, the major metabolite (Fig. 2) . The vincristine disappearance was normalized to an insect microsome control, and no M1 was detected in the control. CYPs 3A4, 3A5, 3A7, and 2E1 showed a statistical difference in vincristine disappearance from the control, but only CYP3A4 and CYP3A5 depleted the substrate more than 10%. M1 accounted for 70% and 50%
of parent drug loss in the CYP3A5 and CYP3A4 incubations, respectively. M2 accounted for 7% product loss with CYP3A5 and 2% with CYP3A4. M4 formation was also increased over the control for both CYP3A5 and CYP3A4 but only accounted for 1% and 4% of the product loss, respectively.
Vincristine metabolite profiles with CYP3A4 and CYP3A5 quantities than the control, but the total amount was only 2% of the total radioactivity for both samples. M5 (21.0-21.3 min) was present in the control but was not detectable as a discrete peak in the other incubations because the M1 peak retention time (20.5-20.7 min) was too close to M5 to allow resolution. For the HPLC assay used to determine the kinetic parameters with UV detection, M5 can be distinguished from M1 by retention time. The radioactivity measured from 10 to 45 min represented at least 95% of the radioactivity present in the samples, and no additional peaks with retention times before 10 min or after 45 min were identified.
Structure determination of vincristine metabolites
M2: M2 showed a protonated molecular ion peak at m/z 839, 14 Da higher than that of the determined by the accurate mass measurement, led us to believe that M2 could be the same as the previously known metabolite of vincristine obtained by its biotransformation catalyzed either by horseradish peroxidase or ceruloplasmin (Ahn et al., 1997) . This hypothesis was further substantiated by a direct comparison of the metabolic products derived from CYP3A5 and horseradish peroxidase reactions of vincristine, which showed identical LC/MS profiles (retention time and MS/MS data) and 1 H NMR data. Hence, the structure of M2 is depicted as shown in Fig. 5A . As noted previously by Ahn et al. (1997) , the formation of M2 could be rationalized by the oxidation of the carbon α to the piperidine nitrogen followed by the fission of This article has not been copyedited and formatted. The final version may differ from this version. 
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Page 15 of 38 C-13 and C-14 bond (Fig. 5A ). An analogous oxidative biotransformation pathway has also been reported for leurosine, another dimeric Vinca alkaloid, when it was catalyzed by the horseradish peroxidase (Goswami et al., 1988) . Furthermore, a similar compound, catharinine, has been reported as a natural product from several Catharanthus species (Andriamialisoa RZ et al., 1978) as a result of the C-13 and C-14 bond fission of the piperidine ring probably following the same metabolic reaction from an appropriate precursor in plants.
In (Tables 2 and 3 ). As noted by Ahn et al. (1997) , both with vincristine and M2, we also observed two sets of resonances for M2 in these solvents, but approximately in 4:1 ratio as opposed to 3:2 that was observed by Ahn et al. in CDCl 3 . The presence of rotamers in CDCl 3 solutions of 18'-desacetylvincristine was postulated previously as a result of a restricted rotation involving the Nformyl group of the NFV moiety (Rao KSPB et al., 1989) . In contrast, in the present investigations, we observed this phenomenon only with M2 and not with vincristine and M3 in Tables 2 and 3 were accomplished after an extensive analysis of 1 H, DQFCOSY, TOCSY, HSQC, HMBC, and 1D ZQFTOCSY spectra. For reliable chemical shift comparisons, vincristine recovered from the CYP3A5 reaction mixture under identical HPLC conditions as that of M3 was used for the NMR experiments to minimize salt induced effects because vincristine is only available commercially as a sulfate salt.
A key, obvious feature observed in the NMR spectrum of M3 when compared to vincristine was the absence of a methoxy resonance (H 3 -23) of the methyl ester in the DHC part of the molecule.
Additionally, several deviations in the chemical shifts of key protons (Table 2 ) and carbons (Table 3) relative to vincristine were also observed. Among them, rather significant departures were observed in the values for both the ethyl side chains. As shown in Table 2 Initially, the structural relationships between M2 and M1, the putative parent of M3, (28 Da) and M2 and M3 (60 Da) were difficult to reconcile based on the mass differences alone. However, inspection of the diol intermediate, which led to M2 as a result of the cleavage of the C-13 and C-14 bond (Fig. 5A ), prompted us to consider an alternative cleavage pathway involving the N-12 and C-13 bond. In fact, such a cleavage should be favored over the C-C bond fission, which led to the formation of M2. As outlined in Fig. 5B , fission of the N-12 and C-13 bond would lead to M1. It is reasonable to assume that the nucleophilic secondary amine thus formed is presumably reactive and under basic conditions underwent an intramolecular amidation reaction leading to the formation of M3 (Fig. 5B ). This proposal is consistent with the loss of 32 Da, a mass equivalent of methanol, from M1 during the transition to M3. Furthermore, the absence of a methoxy resonance, as alluded to earlier, in the NMR spectrum of M3 when compared to vincristine is also in accord with this proposal. The formation of the new amide ring and the structure of M3 were fully characterized by the long range HMBC correlations observed from H-11, H-17, and H-18 to a carbonyl carbon at 185.1 ppm (C-22) and other selected correlations as shown in the Fig. 7 . Accordingly, in the MS/MS spectrum of M3 distinct product ions were observed at m/z 309, 281, and 237 for the modified DHC moiety (Table 1) .
The structure proposed for M1 (precursor of M3) was further supported by the acetylation of M1
immediately following isolation with acetic anhydride, which showed as expected the molecular This article has not been copyedited and formatted. The final version may differ from this version. Da less than the corresponding vincristine ion peak. The structures of M4 and M5 were tentatively proposed as the isomeric epoxides, probably arising as a result of dehydration followed by epoxidation of the resulting C14-C15 double bond of the DHC unit. This is supported by the co-occurrence of vincristine and leurosine in the plant, Catharanthus roseus, most likely as a result of similar metabolic changes. The product ion observed at m/z 353 (Table   1 ) was in concert with the proposed changes in the DHC unit. No additional efforts were taken to further characterize these metabolites.
Enzyme kinetics
The rates of M1 formation were determined for cDNA-expressed CYP3A4 and CYP3A5 (Fig. 9 ).
The K m and V max values were determined for CYP3A4 and CYP3A5 with and without cytochrome b 5 (Table 4) 
Discussion
Our findings show that vincristine oxidation by CYPs is predominantly mediated by CYP3A4 and CYP3A5. This result is in agreement with clinical reports of drug-drug interactions upon coadministration of vincristine with CYP3A inhibitors such as itraconazole and nifedipine (Sathiapalan and El-Solh, 2001; Bohme et al., 1995; Kamaluddin et al., 2001; Fedeli et al., 1989) .
The metabolism of vincristine primarily by CYP3A is also consistent with the physico-chemical features of vincristine, in this case, a large molecular volume. In addition, CYP3A4 and CYP3A5 metabolize vincristine to one major metabolite, M1, a novel compound with chemical modifications to the dihydro-hydroxycatharanthine (DHC) part of the molecule, and two minor metabolites, M2 and M4. Previous in vitro experiments with human hepatocytes described the rapid formation of 3 or 4 unknown compounds from the metabolism of vincristine, vinblastine, and vindesine (Zhou et al., 1994) . These products may include M1 and the minor metabolites (M2 and M4) that we describe herein or other secondary metabolites. Previously, in vitro studies with structurally related Vinca alkaloids, vinblastine and vindesine, showed one major metabolite in human microsomal studies, but the investigators were unable to obtain enough pure material to allow structural identification of the metabolite .
Beyond scale limitations, the chemical instability of M1 that we observed during standard isolation methods may have hampered previous attempts to identify M1 or its related Vinca analogs. We determined the structure of M1 unequivocally by modifying the reactive secondary amine moiety to form two chemically stable derivatives: M3, formed by the base-catalyzed intramolecular amidation of M1, and M1-acetate, generated by acetylation with acetic anhydride.
The structures of these compounds as determined by LC/MS/MS and/or NMR analyses in combination with the previously described structure and formation of M2 (Ahn et al., 1997) In addition to identifying the major metabolite M1, we discovered that CYP3A5 selectively metabolizes vincristine versus CYP3A4, regardless of cytochrome b 5 content; for M1 formation CYP3A5 had a 9 to 14-fold higher intrinsic clearance than CYP3A4. For most tested substrates, the CYP3A5 intrinsic clearance is similar or less than that of CYP3A4 (McConn et al., 2004; Huang et al., 2004; Williams et al., 2002; Patki et al., 2003) . For example, some studies show a modest selectivity (3-fold) for CYP3A5 with midazolam (Huang et al., 2004) , but for other studies, CYP3A5 has equivalent or less activity than CYP3A4 in the formation of 1'-OHmidazolam (Patki et al., 2003; Williams et al., 2002; Walsky and Obach, 2004) . Recently, another study on the metabolism of buprenorphine showed the selective metabolism by CYP3A5 versus CYP3A4 in a screening experiment, but rigorous enzyme kinetics were not presented (Chang et al., 2005) . Thus, our findings with vincristine, which show an order of magnitude greater intrinsic clearance values, provide an unusual example of a very high selectivity for CYP3A5.
This article has not been copyedited and formatted. The final version may differ from this version. probe, have shown mixed results. Some clinical studies showed increased metabolism for CYP3A5*1 carriers (Wong et al., 2004; Yu et al., 2004) , but other studies did not find a statistical difference between the groups (Floyd et al., 2003; Shih and Huang, 2002) . For other CYP3A
substrates, such as tacrolimus, drug disposition is dependent upon CYP3A5 genotype. for each CYP. Statistical differences from the control incubations were calculated for vincristine disappearance using one-way ANOVA analysis, *p<0.05, **p<0.01, ***p<0.001. 
